PBM Math 101: Where the Money Actually Moves
Let’s start with a simple truth:
Most PBM conversations sound like math…
but feel suspiciously like magic tricks.
Lots of numbers.
Lots of percentages.
Lots of confident pointing at slides.
Very little clarity about where the money actually goes.
That’s not an accident. That’s fuzzy logic at work.
The Math Everyone Is Taught to Watch
In workers’ comp, we’re trained to focus on:
AWP discounts
Network penetration
“Fee schedule savings”
It’s familiar. Reassuring. Easy to repeat in a meeting.
It’s also the wrong math.
Because PBMs don’t really make their money on the sticker price.
They make it on what happens after the prescription is filled.
Where Things Get… Fuzzy
In earlier P4Ps, we talked about doing the right math.
This is where that idea stops being philosophical.
We’ve seen — and written about — cases where AWPs on drugs dispensed through PBM-owned pharmacies were inflated dramatically. In some instances, not by a few points… but by multiples of actual acquisition cost.
Think about that for a second.
Same drug. Same pharmacy. Same corporate family. Just a very flexible definition of “average wholesale price.”
That’s not market forces. That’s math being gently nudged until it behaves.
Why Ownership Changes Everything
When a PBM also owns the pharmacy, something subtle but powerful happens.
The system can:
Influence the benchmark
Route the prescription
Capture the spread
All inside the same house.
On paper, the employer still sees a “discount.”
In reality, the baseline quietly moved.
It’s like marking up the price of a couch 5x…
then proudly offering 40% off.
Technically accurate.
Practically misleading.
This Is Why Prosecutors Eventually Get Curious
This isn’t just a theoretical problem. It’s a historical one.
Federal indictments in the PBM and pharmacy space didn’t come from misunderstanding complex math. They came from patterns:
Inflated pricing references
Self-dealing through affiliated pharmacies
Misrepresentation of actual drug costs
Not overnight scandals — slow-burn models that worked too well.
Fuzzy logic scales beautifully… right up until it doesn’t.
Incentives Always Win (Even Over Good Intentions)
Most people in these systems aren’t villains.
But incentives don’t need bad actors to misbehave.
If revenue improves when:
Prices drift upward
Certain drugs are preferred
Prescriptions stay “in network” internally
Then the math will quietly follow the incentive.
You don’t get the outcomes you hope for.
You get the outcomes the math rewards.
The Prodigy Difference: Calm Math, Clean Lines
At Prodigy, we take a pretty boring — but powerful — approach:
If you can’t trace the dollar, we don’t like the model.
That means:
No inflated benchmarks hiding behind discounts
No spread that only shows up if you squint
No benefit to higher prices
When acquisition cost goes down, clients win.
When it goes up, you can see why.
It’s not flashy math.
It’s just honest math.
One Question Worth Asking
If you want to know whether your PBM uses fuzzy logic or real math, try this:
“Can you show me how AWP is set for drugs dispensed through your own pharmacies — and how that compares to what the drug actually costs?”
Not a summary. Not a blended number. Just the comparison.
Clear models answer calmly.
Fuzzy ones suddenly have a lot to say.
The Real Lesson of PBM Math 101
PBM math isn’t complicated. It’s selective.
And in workers’ comp — where payers don’t see receipts and patients don’t choose therapies — selectivity adds up fast.
The next generation of TPAs, risk managers, and leaders won’t win by negotiating harder.
They’ll win by:
Doing the right math
Asking better questions
Choosing partners whose models still make sense in daylight
Because when the math is clean, trust comes easy.
And when the math is fuzzy…someone eventually brings a flashlight.
About P4P
A Strategic Dose of Clarity in a Noisy PBM Market
Written by Prodigy CEO, Del Doherty, P4P delivers sharp, consultative insights for decision-makers who are tired of legacy models, hidden costs, and passive vendors. Each piece is a prescription—cutting through the noise to reveal what actually drives performance in pharmacy benefit management. No fluff. No spin. Just insight that pays off.
